Researchers in labs typically choose the materials backed by simple guidelines on production with reliable analysis
And with more than half of the global population (51% or over 4 billion people) predicted to be either overweight or living with obesity by 2035, investment in obesity drugs is forecast to rise by a compound annual growth rate of 35%38% between 2023 and 2027.9,10 While some GLP-1 treatments currently in the pipeline are set to reach the market in oral tablet form, autoinjectors and pen injectors currently at the forefront of GLP-1 delivery will continue to deliver multiple patient benefits across this significantly expanded market segment
The product is not intended to "diagnose, treat, cure or prevent any disease." FINALLY Easy, affordable treatments that can make a difference
These findings have been replicated across studies lasting two to four years, giving the drug one of the most comprehensive safety and efficacy profiles of any medication in its class
10.1016/j.molmet.2019.09.010 45 MuraliS.AradhyamG
But their story might be even bigger than weight loss